EyePoint Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EYPT Nasdaq 2830 eyepointpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 16th, 2025 12:00 pm
EyePoint Provides Company Update and Anticipated Development Milestones for 2025 - Jan 13th, 2025 12:00 pm
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - Jan 8th, 2025 12:00 pm
EyePoint reports inducement grants under NASDAQ listing rule - Dec 17th, 2024 12:25 pm
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Dec 17th, 2024 12:00 pm
EyePoint doses first patient in second Phase 3 LUCIA clinical trial - Dec 5th, 2024 12:06 pm
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration - Dec 4th, 2024 12:00 pm
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? - Nov 13th, 2024 2:55 pm
EyePoint price target lowered to $33 from $38 at Baird - Nov 12th, 2024 11:45 am
EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Nov 9th, 2024 1:04 pm
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates - Nov 7th, 2024 1:35 pm
EyePoint Pharmaceuticals: Q3 Earnings Snapshot - Nov 7th, 2024 12:37 pm
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments - Nov 7th, 2024 12:00 pm
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing - Nov 5th, 2024 10:10 am
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Nov 4th, 2024 12:00 pm
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - Oct 31st, 2024 8:00 pm
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - Oct 30th, 2024 1:47 am
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? - Oct 29th, 2024 8:49 am
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - Oct 28th, 2024 9:14 pm
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss - Oct 28th, 2024 4:16 pm